Emerging treatments and gene expression profiling in high-risk medulloblastoma.
The past decades have seen an increase in the survival rates of patients with standard-risk medulloblastoma. Efforts have, therefore, been focused on obtaining better results in the treatment of patients with high-risk tumors. In addition to consolidated therapies, novel approaches such as small molecules, monoclonal antibodies, and antiangiogenic therapies that aim to improve outcomes and quality of life are now available through new breakthroughs in the molecular biology of medulloblastoma. The advent of innovative anticancer drugs tested in brain tumors has important consequences for personalized therapy. Gene expression profiling of medulloblastoma can be used to identify the genes and signaling transduction pathways that are crucial for the tumorigenesis process, thereby revealing both new targets for therapy and sensitive/resistance phenotypes. The interpretation of microarray data for new treatments of patients with high-risk medulloblastoma, as well as other poor prognosis tumors, should be developed through a consensus multidisciplinary approach involving oncologists, neurosurgeons, radiotherapists, biotechnologists, bioinformaticists, and other professionals.
Sardi
Iacopo
I
Department of Pediatrics, Onco-hematology and Neuro-surgery Units, University of Florence Medical School, A. Meyer Children's Hospital, Florence, Italy. i.sardi@meyer.it
Cavalieri
Duccio
D
Massimino
Maura
M
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002528:Cerebellar Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D002675:Child, Preschool; D003131:Combined Modality Therapy; D020869:Gene Expression Profiling; D020022:Genetic Predisposition to Disease; D006801:Humans; D008527:Medulloblastoma / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D020411:Oligonucleotide Array Sequence Analysis; D010372:Pediatrics; D015398:Signal Transduction
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal